Latest Earnings Results: Q1 '26
Estimated EPS
-$0.11
Reported EPS
-$0.04
Surprise
+64.43%
Estimated Rev
$80.51M
Reported Rev
$80.92M
Surprise
+0.5%
• Reported GAAP EPS of -$0.04 up 60.00% YoY • AngioDynamics reiterated fiscal year 2027 guidance: net sales of $336.0M - $341.0M, gross margin of 54% 55%, adjusted EBITDA of $13.0M - $16.0M, and adjusted EPS of ($0.29) ($0.24).
Bullish Takeaway
AngioDynamics delivered eighth consecutive quarter of double-digit Med Tech growth, received FDA IDE approval for its NanoKnife BPH study, and reported higher gross margin and adjusted EBITDA.
Bearish Takeaway
AngioDynamics expects lower gross margin in fiscal 2027's second half, cited manufacturing transition and global inflation partially offsetting gross margin, used $15.3M of operating cash, and reported AngioVac sales down 5.9% year over year.
Generated by Stocktwits using AI and company-reported earnings data for Q1 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.07 | -- | -- | N/A |
Q1 '26 | -$0.11 | -$0.04 | 64.43% | BEAT |
Q4 '25 | -$0.09 | -$0.07 | 21.96% | BEAT |
Q3 '25 | -$0.11 | $0.02 | 118.18% | BEAT |
Q2 '25 | -$0.10 | $0.00 | 100.00% | BEAT |